We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.
We believe that our lead product candidates have demonstrated, in clinical trials and/or in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.
 |
|
|
|
|
| RELVAR™ ELLIPTA™ (FF/VI): COPD and Asthma |
|
| ANORO™ ELLIPTA™ (UMEC/VI): COPD |
|
|
|
|
|
| |
| TD-1792: Serious Gram+ Infections |
|
| TD-1607: Serious Gram+ Infections |
|
| |
| TD-1211: Opioid - Induced Constipation |
|
| TD-9855: ADHD and Fibromyalgia |
|
| |
| TD-5108 (velusetrag): GI Motility Dysfunction |
|
| TD-8954: GI Motility Dysfunction |
|
Key:
- ADHD: Attention Deficit Hyperactivity Disorder
- CNS: Central Nervous System
- COPD: Chronic Obstructive Pulmonary Disease
- FF: Fluticasone Furoate
- GI: Gastrointestinal
- LAMA: Long-Acting Muscarinic Antagonist
- MABA: Bifunctional Muscarinic Antagonist-Beta2 Agonist
- UMEC: Umeclidinium
- VI: Vilanterol
In the table above:
- Development Status indicates the most advanced stage of development that has been completed or is in process.
- Phase 1 indicates initial clinical safety testing in healthy volunteers, or studies directed toward understanding the mechanisms of action of the drug.
- Phase 2 indicates further clinical safety testing and preliminary efficacy testing in a limited patient population.
- Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
- Filed indicates that a marketing application has been submitted to a regulatory authority and is under review.
We consider programs in which at least one compound has successfully completed a Phase 2a study showing efficacy and tolerability as having achieved Proof-of-Concept.
